AGIANA PHARMACEUTICALS AS: årsregnskap 2023 vs 2022
Weaker earnings, cash halved-plus
approved 2024-05-06; registry 2024-06-06; journal 2024 489847
Summary
What changed
Comparing Årsregnskap 2023 with 2022 for AGIANA PHARMACEUTICALS AS. Revenue 0 NOK → 235.3k NOK. Net result -2 958 NOK → -2.95m NOK. Equity -2.93m NOK → -5.88m NOK.
On the constructive side: revenue rose; operating result improved. Pressures included: net result weakened; equity eroded; cash fell.
Also worth watching: thin equity buffer; sharp cash drawdown; payroll increased. All figures are taken from the published annual accounts for AGIANA PHARMACEUTICALS AS.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 0 NOK to 235.3k NOK. Calculated
-
↑
Operating result improved
Operating result -2.85m NOK → -2.64m NOK. Calculated
What deteriorated
-
↓
Net result weakened
Net result -2 958 NOK → -2.95m NOK. Calculated
-
↓
Equity eroded
Book equity -2.93m NOK → -5.88m NOK (equity ratio -69.3% → -349.5%). Calculated
-
↓
Cash fell
Bank deposits 4.00m NOK → 1.44m NOK (-63.9% YoY). Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is -349.5% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (4.00m NOK → 1.44m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
Payroll increased
Salary cost 1 279 NOK → 2.50m NOK. Calculated